TY - JOUR
T1 - Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease
AU - Chun, Ho Soo
AU - Lee, Minjong
AU - Lee, Hye Ah
AU - Oh, Seo Yeong
AU - Baek, Hyo Jeong
AU - Moon, Jae Won
AU - Kim, Yeon Jeong
AU - Lee, Jinha
AU - Kim, Hyoeun
AU - Kim, Hwi Young
AU - Yoo, Kwon
AU - Kim, Tae Hun
AU - Kim, Seung Up
N1 - Publisher Copyright:
© 2023 AGA Institute
PY - 2023/2
Y1 - 2023/2
N2 - Background & Aims: International guidelines recommend physical activity for subjects with nonalcoholic fatty liver disease (NAFLD). This study investigated the association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease (CVD) in NAFLD. Methods: In this multicenter, retrospective study, 11,690 NAFLD subjects who underwent a health screening program and were assessed for physical activity (metabolic equivalent task [MET]-min/week) between 2014 and 2020 were recruited. Liver fibrosis was assessed by using the fibrosis-4 index, NAFLD fibrosis score, and FibroScan-AST score, sarcopenia by using multi-frequency bioelectric impedance analysis, and CVD risk by using atherosclerotic CVD (ASCVD) risk score, and coronary artery calcium (CAC) score were calculated. Results: The prevalence of fibrosis, sarcopenia, high probability of ASCVD, and high CAC score significantly decreased with increasing quartiles of physical activity (all P for trend <.001). In a fully adjusted model, physical activity above 600 MET-min/week (≥third quartile) was independently associated with a reduced risk of fibrosis (adjusted odds ratio [aOR] = 0.59; 95% confidence interval [CI], 0.40–0.86), sarcopenia (aOR = 0.72; 95% CI, 0.58–0.88), high probability of ASCVD (aOR = 0.58; 95% CI, 0.46–0.73), and high CAC score (aOR = 0.32; 95% CI, 0.13–0.83; all P <.05). In addition, increasing amounts of physical activity were significantly associated with risk reduction between fibrosis, sarcopenia, and high probability of ASCVD (all P for trend <.001). In subjects with sarcopenic obesity or lean NAFLD, physical activity was also independently associated with reduced risk of fibrosis and high probability of ASCVD (all P <.05). Conclusions: Physical activity showed a protective effect against fibrosis, sarcopenia, and CVD in NAFLD.
AB - Background & Aims: International guidelines recommend physical activity for subjects with nonalcoholic fatty liver disease (NAFLD). This study investigated the association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease (CVD) in NAFLD. Methods: In this multicenter, retrospective study, 11,690 NAFLD subjects who underwent a health screening program and were assessed for physical activity (metabolic equivalent task [MET]-min/week) between 2014 and 2020 were recruited. Liver fibrosis was assessed by using the fibrosis-4 index, NAFLD fibrosis score, and FibroScan-AST score, sarcopenia by using multi-frequency bioelectric impedance analysis, and CVD risk by using atherosclerotic CVD (ASCVD) risk score, and coronary artery calcium (CAC) score were calculated. Results: The prevalence of fibrosis, sarcopenia, high probability of ASCVD, and high CAC score significantly decreased with increasing quartiles of physical activity (all P for trend <.001). In a fully adjusted model, physical activity above 600 MET-min/week (≥third quartile) was independently associated with a reduced risk of fibrosis (adjusted odds ratio [aOR] = 0.59; 95% confidence interval [CI], 0.40–0.86), sarcopenia (aOR = 0.72; 95% CI, 0.58–0.88), high probability of ASCVD (aOR = 0.58; 95% CI, 0.46–0.73), and high CAC score (aOR = 0.32; 95% CI, 0.13–0.83; all P <.05). In addition, increasing amounts of physical activity were significantly associated with risk reduction between fibrosis, sarcopenia, and high probability of ASCVD (all P for trend <.001). In subjects with sarcopenic obesity or lean NAFLD, physical activity was also independently associated with reduced risk of fibrosis and high probability of ASCVD (all P <.05). Conclusions: Physical activity showed a protective effect against fibrosis, sarcopenia, and CVD in NAFLD.
UR - http://www.scopus.com/inward/record.url?scp=85125737359&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125737359&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2021.12.043
DO - 10.1016/j.cgh.2021.12.043
M3 - Article
C2 - 34998993
AN - SCOPUS:85125737359
SN - 1542-3565
VL - 21
SP - 358-369.e12
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 2
ER -